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ABSTRACT 
 
Background: Intellectual disability (ID) is a major public health problem because the 
defect, treatment and rehabilitation require long life both medical and socioeconomic 
assessment. Fragile X syndrome (FXS) is the most common cause of inherited X-linked 
intellectual disabilities (ID) with reduced penetrance. With regard to behavioral and 
emotional phenotype, FXS commonly mixed up with idiopathic autism. The 
prevalence is found higher in males compared to females. In accordance with 
development of various diagnosis techniques, the prevalence of FXS is defining 
worldwide including Indonesia using the simplest techniques 
Objectives: This study was aimed to diagnose genetic cause of ID and to establish the 
prevalence of FXS in the ID population in Central Java, and Yogyakarta Province.  
Method: Screening has been performed since 1994 continuously in high risk 
population (special school with and without autism) using clinical, cytogenetic, and 
FMR1 gene PCR-based molecular approach. Cascade testing was subjected to the 
family members with positive result of FXS and many new cases were disclosed in our 
cohort study. 
Results: The prevalence of FXS among ID population was calculated to be 1.9% 
(5/262) in 1994 and 1.7% (9/527) in 2011. Among autism population it was 
determined to be 6.15% (4/65). Trisomy 21 was found in 14% (74/527) as a major 
cause of ID. 
Conclusion: The prevalence of FXS among screened ID population overtime is 
comparable. 
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INTRODUCTION 
 ID is a public health problem and becoming 
important consideration due to some reasons: 1) high 
prevalence in general population, 2) lifelong disorder, 3) 
expensive cost of management, include direct cost of 
long term care, rehabilitation, special education and 
indirect cost of increased morbidity and mortality since 
individual with ID is more vulnerable in health 
problem
1
, 4) High economic and society dependences, 
and 5) Prevention of ID for improving prognosis 
outcome is absolutely needed to be implemented even 
it is very challenging in low and middle income 
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countries.
2
 The prevalence of ID across the world is 
around 1% and almost two times higher rates in low and 
middle income countries.
3
 Fragile X syndrome (FXS) is 
the most common cause of inherited mental retardation 
and a single gene disorder associated with autism 
spectrum disorders (ASD).
4-6
 The frequency of FXS due 
to full mutation allele is approximately 1 in 2500 in 
males and 1 in 4000 in females.
7-9
 The FXS clinical 
phenotype is caused by imbalance of excitatory 
glutamatergic and inhibitory GABAergic 
neurotransmitters.
10
 It is mostly due to the expansion of 
CGG repeats more than 200 (full mutation) in the 
promotor region of the FMR1 gene that leads 
transcriptional silencing and results in lack of fragile X 
mental retardation protein (FMRP).
11
 Fragile X 
syndrome is the first pathogenic mutations that affect 
trinucleotide repeat expansions (TREs) diseases 
involving non-coding repeats sequences.
12,13
 
 Until the late 1990s, fragile X site cytogenetic 
analysis was used to diagnose FXS. Subsequently, 
molecular techniques has been used to identify the 
FMR1 alleles since the sequence of FMR1 gene has been 
discovered in the beginning of 1990s.
14
 However, in 
developing countries where advanced laboratory 
equipment and services are very minimal and 
unaffordable, cytogenetic techniques are still an option 
to accomplish the FXS diagnosis,
15
 more overly, clinical 
symptoms of FXS especially in younger age is quite 
challenging to be differentiated with other non-
syndromic intellectual disabilities (ID). 
 The prevalence of FXS varies across ethnic groups,
16
 
it is important to provide fragile X allele frequencies for 
all race and across the world, so that general (low-risk) 
and high-risk population screening the incidence of 
FMR1 gene mutation is considered necessarily. 
Population-based screening is the most favorable method 
to identify new FXS cases both clinically and laboratory 
assessment. General population screening to determine 
the diseases and carriers prevalence in both male and 
female have been reported worldwide.
17-21
 Based on the 
American College of Medical Genetics (ACMGs) 
guideline, screening for FXS in high-risk population 
such as ID and autism population-based FXS screening 
have also been done to established FXS prevalence.
5,22-24
 
Various simple and cost-effective DNA-based assay are 
developing with higher sensitivity and specificity to 
meet the requirement of population screening study.
25-28
 
Recently, prevalence studies were also reported from 
other developing countries although mostly done by 
scientist in Saudi Arabia, Malaysia, and Sri Lanka.
25,29,30
 
This study was aimed to define the prevalence of FXS in 
the high-risk population in Indonesia. 
MATERIALS AND METHODS 
 These were cross sectional study designs which 
were done in special school in Central Java and 
Yogyakarta provinces. Individuals who were 
diagnosed with ASD using the criteria of the 
Diagnostic and Statistical Manual of Mental Disorders, 
4th edition, Text Revision (DSM IV-TR) for ASD and 
ID by experienced pediatricians were recruited.
31
 This 
research was approved by the Institutional Review 
Board of the Faculty of Medicine, Diponegoro 
University and dr. Kariadi Hospital Semarang, 
Indonesia. All participants gave their consent in 
written/signed a consent form to participate in this 
study. This study was conducted in six special schools 
in Central Java and Yogyakarta Province. 
 Heparinized peripheral blood vein was collected 
for cytogenetic analysis of the fragile site at Xq27.3 
and chromosomal abnormalities as done previously.
32
 
Deoxyribonucleic acid (DNA) was extracted from 
ethylene diamine tetra acetic acid (EDTA) blood using 
modified salting out method.
33
 The fragile site was 
identified using solid staining followed by Giemsa 
staining for fragile X site confirmation.  The FMR1 
gene was analyzed using a PCR-based method to 
determine the CGG repeat length in the promotor 
region as described previously.
34
 Males with no bands 
and females with only one band were assumed to have 
alleles consisting of high pre-mutation or full mutation 
alleles, therefore, Southern blot analysis was used to 
confirm the diagnosis.
34 
 
RESULTS 
 This study was dedicated to determine the 
prevalence of FXS in the high risk population (ID and 
ASD). The first population study in 1997 among ID 
population in special school, the overall prevalence of 
was 5/262 (1.9%). In all, five children from three 
unrelated families were found to have FMR1 CGG-
repeat expansions. All came from the population 
attending type C (ID) special schools.
22
 
 The second population study in 2007-2010 among 
ID population in special school, of the 527 individuals 
with ID, chromosomal abnormalities were found in 87 
(16.5%). Trisomy 21 was the major chromosomal 
abnormality, identified in 74 patients (14%). In the 
remaining of 445 individuals (162 females and 283 
males), 607 alleles were reported (male has 1 allele, 
female has 2 alleles) i.e. 593 alleles were within the 
normal range (15-44 CGG repeats), 3 alleles in the 
intermediate range (45-55 CGG repeats), 2 alleles in 
the premutation range (between 55 and 200 CGG 
11 
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repeats) and 9 alleles in the full mutation range (> 200 
CGG repeats). The prevalence of FXS is 9/527 (1.7%). 
The prevalence in males and females is 1.5% (5/329) and 
2% (4/198), respectively.
35
 
 The study in high risk (autism) population study, the 
fragile X site and FMR1 full mutation allele were
 identified in 3 out of 65 (4.6%) and 4 out of 65 (6.15 
%) children aged 3 to 17 years (57 boys, 8 girls) 
respectively.
36
  Impairment of social communication 
and interaction domains have been found to be 
dominant in four FXS children with ASD. 
 
 
Table 1. Prevalence of FXS among ID and Autism Population in Indonesia. 
The level of cognitive impairment in FXS usually 
ranging from learning disabilities to severe ID is 
associated with the FMRP level.
37
  In addition to the 
cognitive impairment, behavioral and emotional 
impairment have also been observed as a major problem 
in individuals with FXS.
38-42
 Early intervention has been 
reported in many centers worldwide shows efficacy 
decreasing the risk of severe cognitive impairment, 
improving behavioral problems, emotional, and 
psychosocial abilities in later life. There are numerous 
psycho-pharmacological agents that being used to 
improve behavioral and emotional disorders in FXS 
whose may have impact on cognitive function
43
 
,behavioral and emotional abilities.
44,45
 
Psychopharmacological agents may support the 
effectiveness of non-psychopharmacological 
intervention such as behavior, physical, and speech 
therapy; and both intervention result the improvement 
of cognitive function. The similarity and overlapping 
clinical phenotype, especially in behavioral 
impairments, and neuroanatomical background between 
FXS and ASD encouraging the same approach in FXS 
targeted treatment.
46,47
 
The first FXS population-based study on 262 
subjects at schools with special need in Indonesia 
showed a prevalence of 1.9%.
22
 New cohort of high-risk 
population screening of FXS has been conducted among 
ASD and ID population using fragile X site method 
combine with molecular one.
48,49
 The fragile X site 
expression has been able to detect 3 out of 4 FXS cases 
among autism population that eventually confirmed 
using PCR-based method followed by Southern blot 
method. The prevalence of FXS is 6.15% in ASD 
population in Indonesia.
36
 Similar result also reported 
from a number of studies that have been carried out in 
ASD population varying from 4-7%.
5,23
 The prevalence 
of FXS is 1.7% (considered equal in males and females) 
in ID population. Surprising result had been reported in 
the prevalence of FXS in male and female is equal in
Indonesia, suggested that the prevalence of FXS 
females had been underestimated.
49
 The FXS is an X-
link disorders with reduced penetrance (79% in males, 
35% in females), females usually less affected due to 
the X-inactivation.
50,51
 This study was a continuation of 
the first FXS population-based study with broader 
approach to identify FXS cases, cascade testing to 
identify carriers, and finally, to offer early intervention 
among FXS children. Population-based screening 
method in FXS has been developed related to 
Indonesian condition which is contained more than 
17.000 islands indweled by 237.6 million populations 
with very minimal access to genetic facilities and 
centers. In Java island, the most populated area where 
58 percent of Indonesian population live, only one FXS 
center conducts fragile X diagnosis both cytogenetic 
and molecular diagnosis that is Center for Biomedical 
Research (CEBIOR) Faculty of Medicine Diponegoro 
University. 
With regards to the prevalence and the mode of 
inheritance, FXS screening high-risk population 
program should be performed routinely and initiate by 
the government in Indonesia. On the contrary, health 
care provider, government, and public awareness is 
inadequate with regard to identify FXS and to provide 
basic special need services in order to get better 
outcome. Seminar, workshops, dissemination 
information of fragile X syndrome should also be 
conducted regularly using/ leaflet distribution and/or 
online media to educate clinicians, health care 
professionals, families, researchers and broader 
community to increase awareness the role of genetic 
especially FXS in ID. Using a comprehensive approach 
to whole Indonesian data of FXS overtime and other 
cause of ID, our studies will give a great contribution to 
science, medical community, and stake holders in 
increasing awareness of FXS in Indonesia. In a 
contrary, in developed countries such as European and 
Unites Stated, clinical and molecular guidelines have 
12 
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been established and revised continuously for fragile X 
and fragile X-associated disorders in order to identify 
FXS cases.
52,53
 With regard to the prevalence of FXS, 
similar study is extremely needed to be done in other 
area of Java Island where the rest of 40 percent 
Indonesian population live. 
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